February 29, 2020

SK Biopharma to raise at least W5tr in IPO

PUBLISHED : November 25, 2019 - 10:52

UPDATED : November 25, 2019 - 10:52

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

South Korean drug firm SK Biopharmaceuticals is expected to raise at least 5 trillion won ($4.25 billion) through a planned share sale, analysts said Nov. 25.

The company said that XCOPRI has won approval from the US Food and Drug Administration for the treatment of partial-onset seizures in adults.

Following the FDA approval, SK Biopharmaceuticals will likely speed up its IPO, with its shares slated to be listed early next year, according to them.

SK Biopharmaceuticals, a biopharmaceutical unit of South Korean conglomerate SK Group, submitted a preliminary application for an initial public offering to the Korea Exchange late last month.

SK Securities estimated in a recent research note that the corporate value of SK Biopharmaceuticals, wholly owned by SK Holdings, would reach about 6.2 trillion won.

In an August report, Korea Investment & Securities expected the market capitalization of SK Biopharmaceuticals to range from 5 trillion won to 10 trillion won.

By Ram Garikipati and newswires (

  • 페이스북
  • 트위터
  • sms
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099